Drug Trial Radar · NCT07599410
A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jul 14, 2026
Primary completion
May 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the trial is to investigate the efficacy and safety of HRS9531 tablets versus placebo in participants with type 2 diabetes mellitus who failed to achieve adequate glycemic control on lifestyle intervention alone or on a stable dose of metformin. This study will last 20 weeks.
Conditions
- T2DM
Interventions
HRS9531 TabletDrug
HRS9531 Tablet dose 1
HRS9531 TabletDrug
HRS9531 Tablet dose 2
HRS9531 TabletDrug
HRS9531 Tablet dose 3
HRS9531 TabletDrug
HRS9531 Tablet dose 4
HRS9531 TabletDrug
HRS9531 Tablet dose 5
HRS9531 Tablet placeboDrug
HRS9531 Tablet placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in glycated hemoglobin (HbA1c) relative to baselineTime frame: Week 20.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chaoyang Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.